Mitochondrial complex I as a therapeutic target for Alzheimer's disease

Eugenia Trushina, Sergey Trushin, Md Fayad Hasan

Research output: Contribution to journalReview articlepeer-review


Alzheimer's disease (AD), the most prominent form of dementia in the elderly, has no cure. Strategies focused on the reduction of amyloid beta or hyperphosphorylated Tau protein have largely failed in clinical trials. Novel therapeutic targets and strategies are urgently needed. Emerging data suggest that in response to environmental stress, mitochondria initiate an integrated stress response (ISR) shown to be beneficial for healthy aging and neuroprotection. Here, we review data that implicate mitochondrial electron transport complexes involved in oxidative phosphorylation as a hub for small molecule-targeted therapeutics that could induce beneficial mitochondrial ISR. Specifically, partial inhibition of mitochondrial complex I has been exploited as a novel strategy for multiple human conditions, including AD, with several small molecules being tested in clinical trials. We discuss current understanding of the molecular mechanisms involved in this counterintuitive approach. Since this strategy has also been shown to enhance health and life span, the development of safe and efficacious complex I inhibitors could promote healthy aging, delaying the onset of age-related neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)483-495
Number of pages13
JournalActa Pharmaceutica Sinica B
Issue number2
StatePublished - Feb 2022


  • Alzheimer's disease
  • Complex I inhibitors
  • Healthy aging
  • Integrated stress response
  • Mitochondria
  • Mitochondria signaling
  • Mitochondria targeted therapeutics
  • Neuroprotection

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics


Dive into the research topics of 'Mitochondrial complex I as a therapeutic target for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this